Breast Cancer

Radius Health Receives FDA Fast Track Designation for Elacestrant (10-26-2017)

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for elacestrant, an investigational oral selective estrogen receptor down-regulator/degrader (SERD) as a treatment of women with ER+ and HER2- advanced or metastatic breast... Continue Reading

Immunotherapy Active Against Triple-Negative Breast Cancer (10-12-2017)

October is breast cancer awareness month and patients with triple-negative breast cancer (TNBC) should be aware that data from two clinical trials provide additional evidence that they may derive benefit from checkpoint inhibitor therapy.1-4 About Triple... Continue Reading

LynparzaTM Slows Spread of Inherited Breast Cancer Caused By BRCA Mutations (10-10-2017)

LynparzaTM (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes also appears to slowe the progression of breast cancer caused in part by mutations in the BRCA gene.  BRCA is an inherited condition... Continue Reading

FDA approves new treatment for certain advanced or metastatic breast cancers (10-5-2017)

The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed... Continue Reading

Annual Mammography Starting at Age 40 Prevents the Most Cancer Deaths (09-13-2017)

When to initiate screening for breast cancer, how often to screen, and how long to screen are questions that continue to spark emotional debates. A new study compares the number of deaths that might be prevented as a result of three of the most widely... Continue Reading

FDA Grants Breakthrough Therapy Designation to DS-8201 for HER2-Positive Metastatic Breast Cancer (08-30-2017)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody drug conjugate (ADC), for the treatment of patients with HER2-positive, locally advanced or metastatic breast... Continue Reading

Nipple-Sparing Mastectomy Has Low Rate of Breast Cancer Recurrence (08-1-2017)

Investigators say most women with breast cancer are eligible for this type of mastectomy, which leaves the natural nipple in place Women with breast cancer who undergo nipple-sparing mastectomy (NSM) have a low rate of the cancer returning within the... Continue Reading

Balance and Gait is Negatively Impacted By Chemotherapy Treatment (07-26-2017)

A single chemotherapy treatment can result in a significant negative impact on walking gait and balance, putting patients at an increasing risk for falls, according to a new study involving breast cancer patients conducted by researchers at The Ohio State... Continue Reading

FDA Approves Nerlynx for Treatment of Early Stage HER2-Positive Breast Cancer (07-18-2017)

The U.S. Food and Drug Administration approved Nerlynx (eratinib) for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. Approval was based on the... Continue Reading

Immunotherapy with Checkpoint Inhibitor Durvalumab Show Promise in Triple Negative Breast Cancer (06-22-2017)

Doctors from Yale Cancer Center presented new data at the American Society of Clinical Oncology meeting on the impact of combining the immune checkpoint inhibitor (durvalumab/MEDI4736) with chemotherapy as preoperative treatment for early stage triple... Continue Reading

« Previous PageNext Page »